On Tuesday 12 May 2021, FluoGuide announced the successful completion of a directed issue of around 790,000 shares at a price of SEK 95 per share, raising gross proceeds of SEK 75m. FluoGuide intends to use the proceeds from the issue for: i) one phase II study with the lead product FG001 in new prevalent indications in 2021, ii) preparation of a phase III study in 2022 and iii) preclinical studies on FG002. ABG Sundal Collier acted as Joint Global Coordinator and Bookrunner in the transaction.

Contact

Erik Skog

Erik Skog

Co-Head of ECM and Head of Investment Banking Sweden

erik.skog@abgsc.se +46 8 566 294 71
Benjamin Nordin

Benjamin Nordin

Investment Banking

Benjamin.Nordin@abgsc.se +46 8 566 286 98